Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Automated, scaled, transposon-based production of CAR T cells

1 Sept 2022

Abstract excerpt

BACKGROUND: There is an increasing demand for chimeric antigen receptor (CAR) T cell products from patients and care givers. Here, we established an automated manufacturing process for CAR T cells on the CliniMACS Prodigy platform that is scaled to provide therapeutic doses and achieves gene-transfer with virus-free Sleeping Beauty (SB) transposition. METHODS: We used an advanced CliniMACS Prodigy that is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36096530
DOI: 10.1136/jitc-2022-005189

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Automated, scaled, transposon-based production of CAR T cellsPMID 36096530Read ↗

Enzymatically produced piggyBac transposon vectors for efficient non-viral manufacturing of CD19-specific CAR T cellsSemantic proximity Read ↗

Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and AccessibilitySemantic proximity Read ↗

Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured via electroporation or lentiviral transfection.Semantic proximity Read ↗

Generation and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignancesSemantic proximity Read ↗

Current Non-Viral-Based Strategies to Manufacture CAR-T CellsSemantic proximity Read ↗

Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapiesSemantic proximity Read ↗

Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapiesSemantic proximity Read ↗

Engineering strategies to safely drive CAR T-cells into the futureSemantic proximity Read ↗

Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-T <sub>SCM</sub> cells using <i>qCART</i> , the <i>Quantum pBac</i> -based CAR-T systemSemantic proximity Read ↗

<i>Quantum CART</i> ( <i>qCART</i> ), a <i>piggyBac-based</i> system for development and production of virus-free multiplex CAR-T cell therapySemantic proximity Read ↗

Efficient nonviral integration of large transgenes into human T cells using Cas9-CLIPTSemantic proximity Read ↗

A meta-analysis on safety and efficacy of CD19 directed CAR T-cells generated using sleeping beauty transposon systemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.